Novartis tallies nine tumor reports among Zolgensma recipients, two tied to vector integration
- Novartis says nine tumors have been reported in Zolgensma-treated patients since the 2019 approval; two show evidence of viral vector integration into DNA.
- The other seven have no established causal link to the therapy.
- Novartis notes tumor risk from integration is already in the label and that over 6,000 patients have received the therapy.
- SMA Europe says regulators are assessing the evidence.
💡 Points Based on public reports
Nine cases in 6,000-plus patients is a small number, but two with vector integration hit AAV's soft spot: durable, one-time dosing was always sold on the assumption that the vector stays episomal. Novartis can lean on the label, yet the real exposure is category-wide, since every AAV gene therapy rival and Novartis's own intrathecal follow-on will be asked the same question about long-term surveillance.
Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma ↗